Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
New York City, NY, March 28, 2026 (GLOBE NEWSWIRE) -- Many players are curious about online casinos but hesitate when it comes to depositing money on a new site. A no deposit bonus casino...
-
2026 SteelPower performance report covers male enhancement formula details, ingredient research context, pricing, and guarantee disclosures.
-
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated...
-
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine, underscoring the practice-changing potential of brepocitinib 30 mg once-daily in...
-
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...
-
Gelatide Drops under investigation: 2026 consumer report on Gelatide-1 claims, fake gelatin trick recipe, ingredient research, and refund terms.
-
NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of America’s...
-
NEW YORK, March 28, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26,...
-
Décision du tribunal américain du district Sud de New York dans le cadre du nouveau procès TriZetto
-
Decision of the US District Court for the Southern District of New York in the TriZetto re-trial